![Sander Slootweg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sander Slootweg
Director/Board Member at FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Philip Astley-Sparke | M | 51 | 9 years | |
Robert Coffin | M | 58 | 9 years | |
Michael Davidson | M | 67 |
NewAmsterdam Pharma Holding BV
![]() NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | 4 years |
Sushil Patel | M | 52 | 3 years | |
John Kastelein | M | 70 |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 2 years |
Hugo Slootweg | M | 53 |
Xention Ltd.
![]() Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002.
Azafaros BV
![]() Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands.
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 19 years |
Dieter Weinand | M | 63 | 6 years | |
Marc Ditmarsch | M | 58 |
NewAmsterdam Pharma Holding BV
![]() NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | 4 years |
Juliette Audet | F | 38 |
NewAmsterdam Pharma Holding BV
![]() NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | 4 years |
Morris J. Birnbaum | M | 72 |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 2 years |
Douglas Kling | M | 50 |
NewAmsterdam Pharma Holding BV
![]() NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | 3 years |
Janneke van der Kamp | F | 49 | 1 years | |
Veleka Peeples-Dyer | F | 52 | 1 years | |
David A. Fraser | M | - |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | - |
Louise Kooij | F | 49 | - | |
Stefano Portolano | M | - |
Azafaros BV
![]() Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | 3 years |
James Jacobson | M | - | 2 years | |
Bob Rambo | M | - | 1 years | |
Andrew Schwendenman | M | 47 | 4 years | |
Paolo Pucci | M | 63 | 4 years | |
Christy Oliger | F | 54 | 3 years | |
John Smither | M | 71 | 1 years | |
Hilde Hermansen Steineger | M | 58 |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 7 years |
Joseph Slattery | M | 59 | 7 years | |
Hyam Levitsky | M | 66 | 6 years | |
Kapil Dhingra | M | 64 | 7 years | |
Rob de Ree | M | - |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | - |
Jordi Xiol | M | - |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 3 years |
Jonathan Leff | M | 66 |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 2 years |
Louis Lange | M | 72 | 2 years | |
Silvia Ragno | M | - |
Azafaros BV
![]() Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | 1 years |
Christopher Sarchi | M | 55 | 1 years | |
Konstantinos Xynos | M | 57 | 2 years | |
Annie Neild | F | - | 3 years | |
James Topper | M | 62 | 2 years | |
Mayur Ian Somaiya | M | 50 | 1 years | |
Keith McCullagh | M | 80 |
Xention Ltd.
![]() Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | 16 years |
Nicholas Downing | M | 39 | 2 years | |
Richard Gaster | M | 40 |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 4 years |
Dirk Kersten | M | 49 |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | - |
Patrick Michael Round | M | 65 |
Xention Ltd.
![]() Xention Ltd. Pharmaceuticals: MajorHealth Technology Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002. | 8 years |
Arleen Goldenberg | F | - | - | |
Will Lewis | M | 55 | - | |
Andreas Wallnöfer | M | 63 |
Azafaros BV
![]() Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | - |
Emily Hill | F | 44 | 1 years | |
Mats Blom | M | 59 |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | 5 years |
Somu Subramaniam | M | 69 |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | - |
Carlo Incerti | M | 65 |
Azafaros BV
![]() Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | 4 years |
Søren Møller | M | 56 |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | - |
William Jones | M | 60 | 1 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Netherlands | 33 | 66.00% |
United States | 15 | 30.00% |
United Kingdom | 3 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Sander Slootweg
- Personal Network